Literature DB >> 11179323

Differential biological and adjuvant activities of cholera toxin and Escherichia coli heat-labile enterotoxin hybrids.

C C Bowman1, J D Clements.   

Abstract

Two bacterial products that have been demonstrated to function as mucosal adjuvants are cholera toxin (CT), produced by various strains of Vibrio cholerae, and the heat-labile enterotoxin (LT) produced by some enterotoxigenic strains of Escherichia coli. Although LT and CT have many features in common, they are clearly distinct molecules with biochemical and immunologic differences which make them unique. The goal of this study was to determine the basis for these biological differences by constructing and characterizing chimeric CT-LT molecules. Toxin gene fragments were subcloned to create two constructs, each expressing the enzymatically active A subunit of one toxin and the receptor binding B subunit of the other toxin. These hybrid toxins were purified, and the composition and assembly of CT A subunit (CT-A)-LT B subunit (LT-B) and LT A subunit (LT-A)-CT B subunit (CT-B) were confirmed. Hybrids were evaluated for enzymatic activity, as measured by the accumulation of cyclic AMP in Caco-2 cells, and the enterotoxicity of each toxin was assessed in a patent-mouse assay. The results demonstrated that LT-A-CT-B induces the accumulation of lower levels of cyclic AMP and has less enterotoxicity than either wild-type toxin or the other hybrid. Nonetheless, this hybrid retains adjuvant activity equivalent to or greater than that of either wild-type toxin or the other hybrid when used in conjunction with tetanus toxoid for intranasal immunization of BALB/c mice. Importantly, the ability of LT to induce a type 1 cytokine response was found to be a function of LT-A. Specifically, LT-A-CT-B was able to augment the levels of antigen-specific gamma interferon (IFN-gamma) and interleukin 5 to levels comparable to those achieved with native LT, while CT-A-LT-B and native CT both produced lower levels of antigen-specific IFN-gamma. Thus, these toxin hybrids possess unique biological characteristics and provide information about the basis for differences in the biological activities observed for CT and LT.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11179323      PMCID: PMC98052          DOI: 10.1128/IAI.69.3.1528-1535.2001

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  26 in total

1.  WHO report on infectious diseases.

Authors: 
Journal:  Wkly Epidemiol Rec       Date:  1999-08-20

Review 2.  Cholera toxin and its subunits as potential oral adjuvants.

Authors:  C O Elson
Journal:  Curr Top Microbiol Immunol       Date:  1989       Impact factor: 4.291

3.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

4.  Properties of homogeneous heat-labile enterotoxin from Escherichia coli.

Authors:  J D Clements; R J Yancey; R A Finkelstein
Journal:  Infect Immun       Date:  1980-07       Impact factor: 3.441

Review 5.  New knowledge on pathogenesis of bacterial enteric infections as applied to vaccine development.

Authors:  M M Levine; J B Kaper; R E Black; M L Clements
Journal:  Microbiol Rev       Date:  1983-12

6.  Cloning of a gene (zot) encoding a new toxin produced by Vibrio cholerae.

Authors:  B Baudry; A Fasano; J Ketley; J B Kaper
Journal:  Infect Immun       Date:  1992-02       Impact factor: 3.441

7.  Isolation and characterization of homogeneous heat-labile enterotoxins with high specific activity from Escherichia coli cultures.

Authors:  J D Clements; R A Finkelstein
Journal:  Infect Immun       Date:  1979-06       Impact factor: 3.441

8.  Adjuvant activity of Escherichia coli heat-labile enterotoxin and effect on the induction of oral tolerance in mice to unrelated protein antigens.

Authors:  J D Clements; N M Hartzog; F L Lyon
Journal:  Vaccine       Date:  1988-06       Impact factor: 3.641

9.  In vitro formation of hybrid toxins between subunits of Escherichia coli heat-labile enterotoxin and those of cholera enterotoxin.

Authors:  Y Takeda; T Honda; S Taga; T Miwatani
Journal:  Infect Immun       Date:  1981-11       Impact factor: 3.441

10.  The adjuvant effect of Vibrio cholerae and Escherichia coli heat-labile enterotoxins is linked to their ADP-ribosyltransferase activity.

Authors:  N Lycke; T Tsuji; J Holmgren
Journal:  Eur J Immunol       Date:  1992-09       Impact factor: 5.532

View more
  31 in total

Review 1.  The development and use of vaccine adjuvants.

Authors:  Robert Edelman
Journal:  Mol Biotechnol       Date:  2002-06       Impact factor: 2.695

2.  Prolonged colonization of mice by Vibrio cholerae El Tor O1 depends on accessory toxins.

Authors:  Verena Olivier; Nita H Salzman; Karla J Fullner Satchell
Journal:  Infect Immun       Date:  2007-08-13       Impact factor: 3.441

3.  Expression of cholera toxin B subunit in transgenic rice endosperm.

Authors:  Maria Oszvald; Tae-Jin Kang; Sandor Tomoskozi; Barnabas Jenes; Tae-Geum Kim; Youn-Soo Cha; Laszlo Tamas; Moon-Sik Yang
Journal:  Mol Biotechnol       Date:  2008-07-10       Impact factor: 2.695

Review 4.  Pathogenesis of human enterovirulent bacteria: lessons from cultured, fully differentiated human colon cancer cell lines.

Authors:  Vanessa Liévin-Le Moal; Alain L Servin
Journal:  Microbiol Mol Biol Rev       Date:  2013-09       Impact factor: 11.056

5.  Toll-like receptor 5-dependent immunogenicity and protective efficacy of a recombinant fusion protein vaccine containing the nontoxic domains of Clostridium difficile toxins A and B and Salmonella enterica serovar typhimurium flagellin in a mouse model of Clostridium difficile disease.

Authors:  Chandrabali Ghose; Janneke M Verhagen; Xinhua Chen; Jian Yu; Yaoxing Huang; Olivia Chenesseau; Ciarán P Kelly; David D Ho
Journal:  Infect Immun       Date:  2013-04-01       Impact factor: 3.441

6.  Promotion of colonization and virulence by cholera toxin is dependent on neutrophils.

Authors:  Jessica Queen; Karla J F Satchell
Journal:  Infect Immun       Date:  2013-06-24       Impact factor: 3.441

7.  Oral spore vaccine based on live attenuated nontoxinogenic Bacillus anthracis expressing recombinant mutant protective antigen.

Authors:  R Aloni-Grinstein; O Gat; Z Altboum; B Velan; S Cohen; A Shafferman
Journal:  Infect Immun       Date:  2005-07       Impact factor: 3.441

8.  Safety and immunogenicity of escalating dosages of a single oral administration of peru-15 pCTB, a candidate live, attenuated vaccine against enterotoxigenic Escherichia coli and Vibrio cholerae.

Authors:  Wilbur H Chen; Jose Garza; Monique Choquette; Jennifer Hawkins; Amy Hoeper; David I Bernstein; Mitchell B Cohen
Journal:  Clin Vaccine Immunol       Date:  2014-11-19

9.  A Vibrio cholerae ghost-based subunit vaccine induces cross-protective chlamydial immunity that is enhanced by CTA2B, the nontoxic derivative of cholera toxin.

Authors:  Eno E Ekong; Daniel N Okenu; Jayanti Mania-Pramanik; Qing He; Joseph U Igietseme; Godwin A Ananaba; Deborah Lyn; Carolyn Black; Francis O Eko
Journal:  FEMS Immunol Med Microbiol       Date:  2008-11-18

10.  Induction of mosquitocidal activity in mice immunized with Anopheles gambiae midgut cDNA.

Authors:  B D Foy; T Magalhaes; W E Injera; I Sutherland; M Devenport; A Thanawastien; D Ripley; L Cárdenas-Freytag; J C Beier
Journal:  Infect Immun       Date:  2003-04       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.